You have free access to this content

Cancer

Cover image for Cancer

15 June 2005

Volume 103, Issue 12

Pages 2435–2658

  1. Review Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
      Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma (pages 2435–2446)

      Alan P. Venook

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21123

      • original image
      • original image

      An in-depth status report on epidermal growth factor receptor-targeted agents for the treatment of patients with late-stage colorectal carcinoma is provided.

  2. Original Articles

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast : The University of Pennsylvania experience (pages 2447–2454)

      Roberto J. Santiago, Eleanor E. R. Harris, Li Qin, Wei-Ting Hwang and Lawrence J. Solin

      Version of Record online: 10 MAY 2005 | DOI: 10.1002/cncr.21071

      • original image
      • original image

      This comparison of patients who had early-stage, invasive lobular carcinoma with patients who had invasive ductal carcinoma and who received breast-conservation therapy showed no difference in the 10-year rates of overall survival, cause-specific survival, freedom from distant metastases, local recurrence, or development of contralateral breast carcinoma.

    2. You have free access to this content
      Capecitabine plus docetaxel combination therapy : Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma (pages 2455–2465)

      Shailendra Verma, Dominique Maraninchi, Joyce O'Shaughnessy, Carol Jamieson, Stephen Jones, Miguel Martín, Joseph McKendrick, David Miles, Chris Twelves and John Hornberger

      Version of Record online: 12 MAY 2005 | DOI: 10.1002/cncr.21122

      • original image

      The current pharmacoeconomic analysis showed that capecitabine/docetaxel is a cost-effective treatment for patients with anthracycline-pretreated advanced breast carcinoma.

    3. You have free access to this content
      Women age ≤ 35 years with primary breast carcinoma : Disease features at presentation (pages 2466–2472)

      Ana M. Gonzalez-Angulo, Kristine Broglio, Shu-Wan Kau, Yesmin Eralp, Julie Erlichman, Vicente Valero, Richard Theriault, Daniel Booser, Aman U. Buzdar, Gabriel N. Hortobagyi and Banu Arun

      Version of Record online: 25 APR 2005 | DOI: 10.1002/cncr.21070

      • original image
      • original image

      The authors described a population of women age ≤ 35 years old with breast carcinoma, their characteristics at the time of diagnosis, and the association of these characteristics with disease recurrence and survival.

    4. You have free access to this content
      Perceptions of insurance coverage for screening mammography among women in need of screening (pages 2473–2480)

      Ann Scheck McAlearney, Katherine W. Reeves, Cathy Tatum and Electra D. Paskett

      Version of Record online: 9 MAY 2005 | DOI: 10.1002/cncr.21068

      • original image

      Underserved women in need of a mammogram commonly reported cost as a barrier to screening mammography, yet 40% of these women had an inappropriate perception of their insurance coverage. Providing information about actual costs and coverage levels may reduce the impact of cost as a barrier to screening mammography.

    5. You have free access to this content
      The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up (pages 2481–2484)

      Melinda E. Sanders, Peggy A. Schuyler, William D. Dupont and David L. Page

      Version of Record online: 9 MAY 2005 | DOI: 10.1002/cncr.21069

      • original image

      Small, low-grade, noncomedo ductal carcinoma in situ is the pivotal lesion in understanding the borderline between malignancy and nonmalignancy in the female breast. Noncomedo ductal carcinoma in situ is a nonobligate precursor that involves a very long clinical evolution to invasive carcinoma in approximately 50% of patients when excised incompletely.

    6. Gastrointestinal Disease
      You have free access to this content
      Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin (pages 2485–2490)

      Guido M. Sclabas, Tadashi Uwagawa, Christian Schmidt, Kenneth R. Hess, Douglas B. Evans, James L. Abbruzzese and Paul J. Chiao

      Version of Record online: 28 APR 2005 | DOI: 10.1002/cncr.21075

      • original image
      • original image

      Aspirin repressed tumor formation by PANC-1 cells in an orthotopic mouse model in a prophylactic setting, suggesting a possible mechanism for aspirin's preventive effect in pancreatic carcinoma through inhibition of nuclear factor kappa B activation and a mechanistic link between inflammation and tumorigenesis. Aspirin-mediated antiinflammatory approaches might be an effective strategy to prevent pancreatic carcinoma.

    7. You have free access to this content
      Colorectal carcinoma screening among Hispanics and non-Hispanic whites in a rural setting (pages 2491–2498)

      Beti Thompson, Gloria Coronado, Marian Neuhouser and Lu Chen

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21124

      Colorectal carcinoma ranks as the second most common cancer and the second leading cause of cancer death in the United States. Hispanics are less likely than their non-Hispanic white counterparts to have ever received a fecal occult blood test or sigmoidoscopy/colonoscopy. Little is known about the barriers to screening in the Hispanic population.

    8. Genitourinary Disease
      You have free access to this content
      Undetectable prostate specific antigen at 6–12 months : A new marker for early success in hormonally treated patients after prostate brachytherapy (pages 2499–2506)

      Nicole Miller, Mark E. Smolkin, Eric Bissonette and Dan Theodorescu

      Version of Record online: 25 APR 2005 | DOI: 10.1002/cncr.21077

      • original image
      • original image

      The concept of a prostate-specific antigen (PSA) “nadir” was previously used as a predictive marker for treatment success in patients treated with radiotherapy for localized prostate carcinoma. However, this approach is not applicable when such patients are treated with neoadjuvant or adjuvant hormonal therapies. Therefore, the authors sought to develop a predictive marker for patients treated with brachytherapy (BT) and neoadjuvant and adjuvant androgen ablation. In the current study, the authors report that a PSA level ≤ 0.20 ng/mL measured 6–12 months after BT may be a useful predictive marker for detecting early biochemical success in hormonally treated patients after prostate BT and therefore may be useful in stratifying patients for different types of follow-up, long-term adjuvant therapies, or clinical trials. Longer follow-up periods will be needed to verify whether this is predictive of long-term disease control.

    9. You have free access to this content
      Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis : Gruppo Uro-Oncologico del Nord Est (Northeast Uro-Oncological Group) Penile Cancer Data Base data (pages 2507–2516)

      Vincenzo Ficarra, Filiberto Zattoni, Sergio Cosciani Cunico, Tommaso Prayer Galetti, Lucio Luciani, Andrea Fandella, Stefano Guazzieri, Daniele Maruzzi, Teodoro Sava, Salvatore Siracusano, Stefania Pilloni, Andrea Tasca, Guido Martignoni, Marina Gardiman, Regina Tardanico, Tiziano Zambolin, Antonio Cisternino, Walter Artibani and For the Gruppo Uro-Oncologico del Nord Est (North-Eastern Uro-Oncological Group) Penile Cancer Project

      Version of Record online: 26 APR 2005 | DOI: 10.1002/cncr.21076

      • original image

      The authors reported the experience of a multicenter, multidisciplinary urooncologic group with the treatment of 175 patients who had penile carcinoma. The presence of venous and/or lymphatic embolizations turned out to be an independent predictive variable of pathologic lymph node involvement in a multivariate model.

    10. You have free access to this content
      Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma (pages 2517–2525)

      John S. Lam, Oleg Shvarts, Jonathan W. Said, Allan J. Pantuck, David B. Seligson, Michael E. Aldridge, Matthew H. T. Bui, Xueli Liu, Steve Horvath, Robert A. Figlin and Arie S. Belldegrun

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21127

      • original image
      • original image

      The presence of necrosis in the primary tumor of patients with renal cell carcinoma (RCC) compared with patients without necrosis and the extent of necrosis was found to be associated and correlated with larger size, higher T classification, higher grade, poorer Eastern Cooperative Oncology Group performance status, presence of lymph node disease, presence of metastases, and Ki-67 expression. The presence of this histologic variant was an independent predictor of poor survival in patients with localized, but not metastatic, RCC.

    11. Head and Neck Disease
      You have free access to this content
      Clinical and immunohistologic typing of salivary duct carcinoma : A report of 50 cases (pages 2526–2533)

      Michael Jaehne, Kerstin Roeser, Thorsten Jaekel, Jan David Schepers, Natalie Albert and Thomas Löning

      Version of Record online: 17 MAY 2005 | DOI: 10.1002/cncr.21116

      • original image
      • original image
      • original image

      The authors analyzed the clinical, molecular, and genetic profile of salivary duct carcinoma (SDC) and identified prognostic factors.

    12. You have free access to this content
      Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck (pages 2534–2543)

      David L. Schwartz, R. Bruce Montgomery, Bevan Yueh, Michael Donahue, Yoshimi Anzai, Raylene Canby, Raelene Buelna, Leslie Anderson, Charles Boyd, Janice Hutson and Kathryn Keegan

      Version of Record online: 26 APR 2005 | DOI: 10.1002/cncr.21085

      • original image

      Patients with locally advanced head and neck squamous cell carcinoma were treated with induction docetaxel/carboplatin, followed by concurrent docetaxel/carboplatin and accelerated radiotherapy. Early findings suggested feasibility, favorable toxicity, and promising activity for this treatment strategy.

    13. You have free access to this content
      Radiotherapy alone or combined with surgery for salivary gland carcinoma (pages 2544–2550)

      William M. Mendenhall, Christopher G. Morris, Robert J. Amdur, John W. Werning and Douglas B. Villaret

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21083

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors showed that the optimal treatment for salivary gland carcinomas was surgery, and that postoperative radiotherapy was associated with an improved outcome for patients with advanced-stage disease, incomplete resection, and/or high-grade histology. In the current study, a modest subset of patients were cured with radiotherapy alone.

    14. Hematologic Malignancies
      You have free access to this content
      Interferon α therapy for patients with essential thrombocythemia : Final results of a phase II study initiated in 1986 (pages 2551–2557)

      Rashid Saba, Elias Jabbour, Francis Giles, Jorge Cortes, Moshe Talpaz, Susan O'Brien, Emil J. Freireich, Guillermo Garcia-Manero, Hagop Kantarjian and Srdan Verstovsek

      Version of Record online: 28 APR 2005 | DOI: 10.1002/cncr.21086

      • original image
      • original image

      The results of this Phase II study reinforced the findings of other investigations who evaluated the role of interferon-α (IFN-α) for the treatment of essential thrombocythemia (ET). The apparent ability of IFN-α to reverse disease pathology and possibly modify the clinical course of patients with ET warrants its investigation in larger, prospective trials.

    15. Hepatobiliary Disease
      You have free access to this content
      Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma (pages 2558–2565)

      Luca Beneduce, Francesco Castaldi, Maria Marino, Santina Quarta, Mariagrazia Ruvoletto, Luisa Benvegnù, Fiorella Calabrese, Angelo Gatta, Patrizia Pontisso and Giorgio Fassina

      Version of Record online: 10 MAY 2005 | DOI: 10.1002/cncr.21106

      • original image
      • original image
      • original image
      • original image

      The data presented here constitute the first evidence of the occurrence of circulating squamous cell carcinoma antigen immunoglobulin M (SCCA-IgM) immune complexes in patients with hepatocellular carcinoma. The results indicated that SCCA-IgM immune complexes are useful as biomarkers for the diagnosis of hepatocellular carcinoma.

    16. Lung Disease
      You have free access to this content
      Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma (pages 2566–2574)

      Kuan-Yu Chen, Chia-Hsuin Chang, Chong-Jen Yu, Sow-Hsong Kuo and Pan-Chyr Yang

      Version of Record online: 25 APR 2005 | DOI: 10.1002/cncr.21087

      • original image
      • original image

      In the current study, adenocarcinoma was predominant in female patients and became a more emergent problem than other histologic types among patients with lung carcinoma in Taiwan, potentially raising the importance of studies regarding the benefit of population diversity in new antitumor therapies, such as gefitinib. Female patients with lung carcinoma had a better prognosis than male patients in the group ages 50–69 years, warranting further studies of the potential prognostic factors associated with middle-aged patients, such as hormone status.

    17. You have free access to this content
      Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters (pages 2575–2583)

      Burcak Vural, Lin-Chi Chen, Pinar Saip, Yao-Tseng Chen, Zeki Ustuner, Mithat Gonen, Andrew J. G. Simpson, Lloyd J. Old, Ugur Ozbek and Ali O. Gure

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21088

      • original image
      • original image
      • original image
      • original image
      • original image

      The authors described anti–Sry-like high mobility group box (SOX) Group B and Zinc-finger gene of the cerebellum (ZIC)2 antibodies as two of the most frequently observed antigenic reactivities in small cell lung carcinoma. The association of these antibodies with parameters of more indolent disease, in the absence of paraneoplastic disease, suggested that SOX Group B and ZIC2 antigens can potentially be good therapeutic targets for immunotherapy. The authors reported that further studies are warranted to understand the underlying immune response.

    18. Melanoma
      You have free access to this content
      A phase II study of bortezomib in the treatment of metastatic malignant melanoma (pages 2584–2589)

      Svetomir N. Markovic, Susan M. Geyer, Fitzroy Dawkins, William Sharfman, Mark Albertini, William Maples, Paula M. Fracasso, Tom Fitch, Patricia LoRusso, Alex A. Adjei and Charles Erlichman

      Version of Record online: 10 MAY 2005 | DOI: 10.1002/cncr.21108

      • original image

      The authors reported the results of a Phase II clinical trial using single-agent bortezomib therapy for the treatment of metastatic malignant melanoma. The study did not demonstrate sufficient clinical efficacy for further development of this treatment regimen in patients with metastatic melanoma.

    19. You have free access to this content
      Temozolomide plus thalidomide in patients with brain metastases from melanoma : A Phase II study (pages 2590–2597)

      Wen-Jen Hwu, Eric Lis, Jennifer H. Menell, Katherine S. Panageas, Lynne A. Lamb, Janene Merrell, Linda J. Williams, Susan E. Krown, Paul B. Chapman, Philip O. Livingston, Jedd D. Wolchok and Alan N. Houghton

      Version of Record online: 28 APR 2005 | DOI: 10.1002/cncr.21081

      • original image

      In the current Phase II study examining the efficacy and safety of temozolomide plus thalidomide in chemotherapy-naive patients with brain metastases, 3 patients had a complete or partial response (12% intent to treat), and 7 patients had a minor response or stable disease in the brain. However, 5 of these 10 patients had disease progression at extracranial sites. The current study suggested that temozolomide plus thalidomide is a promising oral regimen for brain metastases from malignant melanoma.

    20. Neuro-Oncology
      You have free access to this content
      Supratentorial extraventricular ependymal neoplasms : A clinicopathologic study of 32 patients (pages 2598–2605)

      Shanop Shuangshoti, Elisabeth J. Rushing, Hernando Mena, Cara Olsen and Glenn D. Sandberg

      Version of Record online: 28 APR 2005 | DOI: 10.1002/cncr.21111

      • original image
      • original image

      Thirty-two archival cases of extraventricular ependymal neoplasms of the cerebral hemispheres were investigated to determine the prognostic impact of clinicopathologic parameters including flow cytometry, the proliferation (Ki-67) labeling index, and p53 expression.

    21. You have free access to this content
      Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors : The Sherbrooke experience (pages 2606–2615)

      David Fortin, Annick Desjardins, Andrew Benko, Theophylle Niyonsega and Marie Boudrias

      Version of Record online: 4 MAY 2005 | DOI: 10.1002/cncr.21112

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The authors report encouraging results in the treatment of malignant brain tumors with the use of the osmotic blood-brain barrier disruption approach to maximize chemotherapy delivery to the central nervous system.

    22. Discipline

      Diagnostic Imaging
      You have free access to this content
      Interobserver reliability of computed tomography-derived primary tumor volume measurement in patients with supraglottic carcinoma (pages 2616–2622)

      Suresh K. Mukherji, Alicia Y. Toledano, Clifford Beldon, Ilona M. Schmalfuss, Jay S. Cooper, JoRean D. Sicks, Robert Amdur, Scott Sailer, Laurie A. Loevner, Phil Kousouboris and Kian Ang

      Version of Record online: 10 MAY 2005 | DOI: 10.1002/cncr.21072

      • original image
      • original image
      • original image
      • original image
      • original image

      Macroscopic (“gross”) tumor volume (GTV) measurements were reliable and reproducible when performed by neuroradiologists and radiation oncologists who were experienced in the interpretation of computed tomography scans of the extracranial head and neck in patients with squamous cell carcinoma of the supraglottic larynx. The results implied that the correlation between GTV and local control should be reproducible across institutions.

    23. Medical Oncology
      You have free access to this content
      Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module : A pilot experience (pages 2623–2628)

      Cary A. Presant, Erin Thompson, Brian LeBerthon, Lori Vergara and Priscilla McGowen

      Version of Record online: 17 MAY 2005 | DOI: 10.1002/cncr.21090

      • original image
      • original image
      • original image

      A geriatric oncology module (GOM) was successfully developed to measure functionality, symptoms, and quality of life. The GOM indicated that weekly paclitaxel or paclitaxel plus carboplatin produced measurable palliation in geriatric oncology patients.

    24. You have free access to this content
      Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin (pages 2629–2635)

      Georgios Chamilos, Aristotle Bamias, Eleni Efstathiou, Pagona M. Zorzou, Efstathios Kastritis, Evagelos Kostis, Christos Papadimitriou and Meletios A. Dimopoulos

      Version of Record online: 26 APR 2005 | DOI: 10.1002/cncr.21089

      The current study evaluated the role of moxifloxacin in the outpatient management of cancer patients with low-risk febrile neutropenia, as identified using a recently proposed risk assessment model. Overall, moxifloxacin was found to be a highly effective and safe regimen.

    25. Pediatric Oncology
      You have free access to this content
      Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction (pages 2636–2642)

      Lucie Lafay-Cousin, Stefan Holm, Ibrahim Qaddoumi, Gary Nicolin, Ute Bartels, Uri Tabori, Annie Huang and Eric Bouffet

      Version of Record online: 28 APR 2005 | DOI: 10.1002/cncr.21091

      • original image

      The current study reports a pilot experience on weekly vinblastine in low-grade glioma children who developed carboplatin hypersensitivity. The experience suggests that vinblastine is a valuable and safe option in carboplatin hypersensitive patients.

    26. Translational Research
      You have free access to this content
      Abdominal obesity, insulin resistance, and colon carcinogenesis are increased in mutant mice lacking gastrin gene expression (pages 2643–2653)

      Stephanie L. Cowey, Michael Quast, Ligia Maria Belalcazar, Jingwa Wei, Xiaoling Deng, Randall Given and Pomila Singh

      Version of Record online: 29 APR 2005 | DOI: 10.1002/cncr.21094

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Abdominal obesity and insulin resistance are risk factors for colon carcinoma. In the current studies, the authors observed a significant increase in the abdominal obesity and insulin resistance in gastrin gene knockout (GAS-KO) mice that lacked gastrin gene expression. The risk of colon carcinogenesis in response to azoxymethane was increased in obese versus lean GAS-KO mice, whereas the risk was the lowest in the wild type littermates. The current results suggested that normally circulating gastrins may reduce the risk of colon carcinogenesis by perhaps maintaining normal metabolic homeostasis.

  3. Correspondence

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
      Author reply (page 2655)

      Yoshito Itoh, Akiko Makiyama and Takeshi Okanoue

      Version of Record online: 9 MAY 2005 | DOI: 10.1002/cncr.21118

    3. You have free access to this content
      Glucocorticoid administration in antiemetic therapy: Is it safe? (page 2656)

      Hans Peter Rutz and Ingrid Herr

      Version of Record online: 26 APR 2005 | DOI: 10.1002/cncr.21067

    4. You have free access to this content
      Author reply (pages 2656–2657)

      Karsten Münstedt, Marek Zygmunt and Richard von Georgi

      Version of Record online: 26 APR 2005 | DOI: 10.1002/cncr.21066

  4. Erratum

    1. Top of page
    2. Review Articles
    3. Original Articles
    4. Correspondence
    5. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION